These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22028406)

  • 1. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.
    Janas L; Stachowiak G; Glowacka E; Piwowarczyk I; Kajdos M; Soja M; Masternak M; Nowak M
    Ginekol Pol; 2024; 95(5):321-327. PubMed ID: 36597746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer.
    Kicman A; Gacuta E; Kulesza M; Będkowska EG; Marecki R; Klank-Sokołowska E; Knapp P; Niczyporuk M; Ławicki S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
    Będkowska GE; Ławicki S; Gacuta E; Pawłowski P; Szmitkowski M
    J Ovarian Res; 2015 May; 8():27. PubMed ID: 25935153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer.
    Hu D; Qian J; Yin F; Wei B; Wang J; Zhang H; Yang H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():170-175. PubMed ID: 38663180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.
    Gaillard DHK; Lof P; Sistermans EA; Mokveld T; Horlings HM; Mom CH; Reinders MJT; Amant F; van den Broek D; Wessels LFA; Lok CAR; ;
    Int J Gynecol Cancer; 2024 May; 34(5):713-721. PubMed ID: 38388177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
    Urban N; Hawley S; Janes H; Karlan BY; Berg CD; Drescher CW; Manson JE; Palomares MR; Daly MB; Wactawski-Wende J; O'Sullivan MJ; Thorpe J; Robinson RD; Lane D; Li CI; Anderson GL
    Gynecol Oncol; 2015 Nov; 139(2):253-60. PubMed ID: 26343159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses.
    Ionescu CA; Matei A; Navolan D; Dimitriu M; Bohâltea R; Neacsu A; Ilinca C; Ples L
    Medicine (Baltimore); 2018 Aug; 97(31):e11762. PubMed ID: 30075600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection.
    Fritz-Rdzanek A; Grzybowski W; Beta J; Durczyński A; Jakimiuk A
    Oncol Lett; 2012 Sep; 4(3):385-389. PubMed ID: 22984370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Dhar C; Ramachandran P; Xu G; Pickering C; Čaval T; Wong M; Rice R; Zhou B; Srinivasan A; Aiyetan P; Chu CW; Moser K; Herzog TJ; Olawaiye AB; Jacob F; Serie D; Lindpaintner K; Schwarz F
    Br J Cancer; 2024 Jun; 130(10):1716-1724. PubMed ID: 38658783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
    Cho H; Hur HW; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
    Cancer Immunol Immunother; 2009 Jan; 58(1):15-23. PubMed ID: 18414853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.
    Lee YJ; Kim W; Hong S; Lee YJ; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.
    Babic A; Cramer DW; Kelemen LE; Köbel M; Steed H; Webb PM; Johnatty SE; deFazio A; Lambrechts D; Goodman MT; Heitz F; Matsuo K; Hosono S; Karlan BY; Jensen A; Kjær SK; Goode EL; Pejovic T; Moffitt M; Høgdall E; Høgdall C; McNeish I; Terry KL
    Cancer Causes Control; 2017 May; 28(5):459-468. PubMed ID: 28050675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
    Abdelrazek MA; Nageb A; Barakat LA; Abouzid A; Elbaz R
    Breast Cancer; 2022 May; 29(3):507-515. PubMed ID: 34994942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine Learning-Enhanced Extraction of Biomarkers for High-Grade Serous Ovarian Cancer from Proteomics Data.
    De Silva S; Alli-Shaik A; Gunaratne J
    Sci Data; 2024 Jun; 11(1):685. PubMed ID: 38918474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
    Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
    Cramer DW; Fichorova RN; Terry KL; Yamamoto H; Vitonis AF; Ardanaz E; Aune D; Boeing H; Brändstedt J; Boutron-Ruault MC; Chirlaque MD; Dorronsoro M; Dossus L; Duell EJ; Gram IT; Gunter M; Hansen L; Idahl A; Johnson T; Khaw KT; Krogh V; Kvaskoff M; Mattiello A; Matullo G; Merritt MA; Nodin B; Orfanos P; Onland-Moret NC; Palli D; Peppa E; Quirós JR; Sánchez-Perez MJ; Severi G; Tjønneland A; Travis RC; Trichopoulou A; Tumino R; Weiderpass E; Fortner RT; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):790-804. PubMed ID: 29661801
    [No Abstract]   [Full Text] [Related]  

  • 19. Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer.
    Zhang T; Chu L; Tan W; Ye C; Dong H
    Clin Respir J; 2024 May; 18(5):e13774. PubMed ID: 38742362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Cutoff Point and Diagnostic Value of the Neutrophil-to-Lymphocyte Ratio in Predicting Ovarian Cancer Compared to Pathological Findings.
    Hosseini MS; Amiri F; Rezapour M; Ashraf Ganjoie T; Farzaneh F; Arab M; Talayeh M; Beheshti Rooy R; Hadi F
    Asian Pac J Cancer Prev; 2024 Mar; 25(3):971-976. PubMed ID: 38546079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.